Boston Trust Walden’s Regeneron Pharmaceuticals REGN Stock Holding History

Boston Trust Walden’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$744K	Hold	1,193	–	–	0.01%	310
2026 Q1	$922K	Sell	1,193 -260	-18%	-$199K	0.01%	291
2025 Q4	$1.12M	Hold	1,453	–	–	0.01%	274
2025 Q3	$817K	Hold	1,453	–	–	0.01%	295
2025 Q2	$763K	Hold	1,453	–	–	0.01%	296
2025 Q1	$922K	Hold	1,453	–	–	0.01%	281
2024 Q4	$1.04M	Hold	1,453	–	–	0.01%	280
2024 Q3	$1.53M	Sell	1,453 -20	-1%	-$22.3K	0.01%	265
2024 Q2	$1.55M	Hold	1,473	–	–	0.01%	258
2024 Q1	$1.42M	Hold	1,473	–	–	0.01%	264
2023 Q4	$1.29M	Hold	1,473	–	–	0.01%	265
2023 Q3	$1.21M	Hold	1,473	–	–	0.01%	266
2023 Q2	$1.06M	Hold	1,473	–	–	0.01%	276
2023 Q1	$1.21M	Buy	1,473 +165	+13%	+$124K	0.01%	266
2022 Q4	$944K	Hold	1,308	–	–	0.01%	283
2022 Q3	$901K	Hold	1,308	–	–	0.01%	276
2022 Q2	$773K	Hold	1,308	–	–	0.01%	285
2022 Q1	$914K	Hold	1,308	–	–	0.01%	285
2021 Q4	$826K	Hold	1,308	–	–	0.01%	298
2021 Q3	$792K	Buy	1,308 +8	+0.6%	+$4.97K	0.01%	297
2021 Q2	$726K	Hold	1,300	–	–	0.01%	305
2021 Q1	$615K	Hold	1,300	–	–	0.01%	307
2020 Q4	$628K	Hold	1,300	–	–	0.01%	304
2020 Q3	$728K	Sell	1,300 -12	-0.9%	-$7.28K	0.01%	294
2020 Q2	$818K	Hold	1,312	–	–	0.01%	292
2020 Q1	$641K	Sell	1,312 -13	-1%	-$5.36K	0.01%	292
2019 Q4	$498K	Sell	1,325 -125	-9%	-$42.1K	0.01%	323
2019 Q3	$402K	Hold	1,450	–	–	0.01%	335
2019 Q2	$454K	Hold	1,450	–	–	0.01%	335
2019 Q1	$595K	Hold	1,450	–	–	0.01%	324
2018 Q4	$542K	Hold	1,450	–	–	0.01%	320
2018 Q3	$586K	Hold	1,450	–	–	0.01%	327
2018 Q2	$500K	Buy	1,450 +250	+21%	+$78.2K	0.01%	329
2018 Q1	$413K	Hold	1,200	–	–	0.01%	345
2017 Q4	$451K	Buy	1,200 +150	+14%	+$60.8K	0.01%	342
2017 Q3	$469K	Buy	1,050 +50	+5%	+$23.8K	0.01%	341
2017 Q2	$491K	Hold	1,000	–	–	0.01%	334
2017 Q1	$388K	Hold	1,000	–	–	0.01%	329
2016 Q4	$367K	Hold	1,000	–	–	0.01%	326
2016 Q3	$402K	Hold	1,000	–	–	0.01%	319
2016 Q2	$349K	Hold	1,000	–	–	0.01%	327
2016 Q1	$360K	Hold	1,000	–	–	0.01%	325
2015 Q4	$543K	Hold	1,000	–	–	0.01%	308
2015 Q3	$465K	Hold	1,000	–	–	0.01%	321
2015 Q2	$510K	Hold	1,000	–	–	0.01%	316
2015 Q1	$451K	Hold	1,000	–	–	0.01%	316
2014 Q4	$410K	Hold	1,000	–	–	0.01%	320
2014 Q3	$361K	Hold	1,000	–	–	0.01%	321
2014 Q2	$282K	Hold	1,000	–	–	﹤0.01%	326
2014 Q1	$300K	Hold	1,000	–	–	﹤0.01%	307
2013 Q4	$275K	Hold	1,000	–	–	﹤0.01%	319
2013 Q3	$313K	Hold	1,000	–	–	﹤0.01%	298
2013 Q2	$225K	Buy	+1,000	New	+$233K	﹤0.01%	308

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Boston Trust Walden's REGN Position: Q2 2026 in Review

Boston Trust Walden held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 1,193 shares worth $744K. The position accounts for 0.01% of the portfolio, ranked #310.

Boston Trust Walden first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.55M in Q2 2024. 474 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Boston Trust Walden held 1,193 shares of Regeneron Pharmaceuticals worth $744K as of Q2 2026.
Boston Trust Walden left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.01% of Boston Trust Walden's portfolio in Q2 2026, its #310 holding.
Boston Trust Walden first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Boston Trust Walden's Regeneron Pharmaceuticals position peaked at $1.55M in Q2 2024.
474 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Boston Trust Walden's 13F filing for Q2 2026, filed 24 Jul 2026.